Artikel
Clinicopathological significance of novel CTCF and eIF4G biomarkers in glioma patients
Die klinisch-pathologische Bedeutung der neuen Biomarker CTCF und eIF4G bei Gliompatienten
Suche in Medline nach
Autoren
-
Friederike C. Schröder
- Universitätsklinikum Magdeburg, Klinik für Neurochirurgie, Magdeburg, Deutschland
-
Belal Neyazi
- Universitätsklinikum Magdeburg, Klinik für Neurochirurgie, Magdeburg, Deutschland
-
Ludwig Wilkens
- Klinikum Nordstadt Hannover, Institut für Pathologie, Hannover, Deutschland
-
I. Erol Sandalcioglu
- Universitätsklinikum Magdeburg, Klinik für Neurochirurgie, Magdeburg, Deutschland
-
Claudia A. Dumitru
- Universitätsklinikum Magdeburg, Klinik für Neurochirurgie, Magdeburg, Deutschland
| Veröffentlicht: | 8. Mai 2019 |
|---|
Gliederung
Text
Objective: The diagnosis and treatment of gliomas remains a major challenge. In recent years, the identification of specific tumor markers has gained relevance for the prognosis and further therapeutic treatment decisions in this type of tumors. CCCTC-binding transcription factor (CTCF) and the Eukaryotic translation initiation factor 4G (eIF4G) are both involved in the early regulation of genetic and epigenetic mechanisms in tumor cells.
Here, we investigated the prognostic value of CTCF and eIF4G for the overall and the progression-free survival of glioma patients. Furthermore, we examined a possible impact and association of these markers with the progress of gliomas.
Methods: Expression and localization of CTCF and eIF4G were assessed immunohistochemically in tissue microarrays from patients with gliomas WHO grade II (n=23), III (n=20) and IV (GBM) (n=113). Survival analysis was performed by Kaplan-Meier estimate, log rank-test and Cox proportional hazard regression. Correlations between these markers and glioma grade were determined by Spearman’s rank correlation coefficient.
Results: GBM patients with high tumor levels of CTCF had a significantly longer overall survival (p=0.003, log-rank) and progression-free survival (p=0.029, log-rank) than patients with low levels of CTCF. Furthermore, patients with high expression of CTCF and methylated status of the previously-described marker MGMT had a threefold better overall survival than those with low CTCF expression and an unmethylated MGMT status. Multivariate Cox regression analysis demonstrated that CTCF (either alone or in combination with MGMT) was an independent prognostic factor for the survival of GBM patients. EIF4G showed no prognostic significance regarding survival; however, it correlated positively with the malignancy grade of the gliomas (Rho=0.477, p<0.001, Spearman).
Conclusion: Our study identified two novel markers in different types of glioma. These findings might help identify novel mechanisms and targets for improved therapeutic strategies in gliomas.
